Key takeaways
- SAR 80-100K per-cycle IV induction cost for efgartigimod in the GCC; annual maintenance runs SAR 300,000-600,000 at four to six cycles/yr
- 60-70% Bupa Arabia's approval rate under its 2023 PA criteria, the GCC's most codified private-payer pricing pathway
- SAR 180-250K NPHC exceptional-access threshold/yr for Saudi nationals without VHI, MGFA Class III-IV with documented ICU risk
- 2025-2026 estimated timeline for routine NPHC formulary coverage, the pending catalyst that replaces channel-by-channel pricing with one reference price
GCC gMG runs on three parallel access channels, each pricing the same drug differently, until NPHC's expected 2025-2026 formulary designation replaces the structure with a single reference price.
Generalised MG has no formal NPHC coverage programme, unlike SMA or PNH. Access to efgartigimod, the only FcRn antagonist registered in the region, runs through three separate routes that each price differently: hospital pharmacy committee approval requiring MGFA Class III-IV disease and failure of two or more immunosuppressive lines; private VHI pre-authorisation, fastest in the UAE under mandatory insurance law at one to four weeks; or an NPHC special application assessed case by case with no formally defined pathway. Efgartigimod's IV induction cycle of four infusions costs SAR 80,000-100,000 in the GCC, against a US WAC equivalent above SAR 300,000 per cycle, with annual maintenance at four to six cycles a year running SAR 300,000-600,000. The subcutaneous formulation costs roughly 80% of the IV price and is preferred for home self-injection.
Private insurers are the furthest ahead on codifying a price and access pathway. Bupa Arabia's 2023 policy requires AChR-antibody-positive generalised MG, MGFA Class III-IV, failure of at least two immunosuppressive lines, and a documented MGFA-TC composite score of three or higher, clearing at a 60-70% approval rate. The NPHC route sets a materially higher bar, MGFA Class IV or myasthenic crisis plus at least three failed immunosuppressive lines, and reaches a defined exceptional-access threshold of SAR 180,000-250,000 a year for Saudi nationals without VHI coverage. argenx is actively pursuing routine NPHC engagement, with formulary coverage estimated for 2025-2026, the catalyst that would collapse three channel-specific prices into one reference price a new entrant must plan against now.
GCC gMG pricing — three access channels, three prices, one pending formulary catalyst
| Access Channel | Approval Timeline | Price Basis | Estimated Annual Cost |
|---|---|---|---|
| Private VHI pre-authorisation (fastest, UAE) | 1-4 weeks | Bupa Arabia-style PA criteria, 60-70% approval rate | SAR 300,000-600,000/yr (IV); ~80% of that for SC |
| Hospital pharmacy committee | 4-12 weeks | MGFA III-IV, 2+ IST failures, AChR+ documentation | Same SAR 300,000-600,000/yr basis, hospital-negotiated |
| NPHC exceptional application (no formal pathway) | Case-by-case | MGFA IV or crisis, 3+ failed IST lines | SAR 180,000-250,000/yr threshold for Saudi-national exceptional access |
Sources: argenx GCC market access documentation 2024; NPHC programme scope; Bupa Arabia formulary and PA criteria 2023; GCC private insurance MG PA data.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- How does the same drug price differently across VHI, hospital pharmacy committee, and NPHC exceptional-access channels, and which channel should a launch plan prioritise first? • Channel-by-channel price basis and approval-timeline comparison • VHI's 1-4 week UAE turnaround versus HPC's longer cycle • the sequencing case for a phased channel strategy
- What does Bupa Arabia's 60-70% approval rate under its 2023 PA criteria imply for a new entrant's private-insurance pricing and eligibility design? • Bupa Arabia PA-criteria breakdown • the MGFA-TC composite-score threshold • approval-rate benchmarking against other GCC private insurers
- What price should a new entrant target once NPHC's expected 2025-2026 formulary designation replaces the three-channel structure with a single reference price? • NPHC exceptional-access threshold (SAR 180,000-250,000/yr) as the pre-formulary anchor • the SC-versus-IV pricing differential • a target formulary-price range
What's inside
-
1 · The Binding Constraint 2 pp
- Why three parallel access channels, not one negotiated price, define GCC gMG pricing today
- Pressure-tested against efgartigimod's existing channel-specific pricing before the rest of the model is built out
-
2 · Price Ladder — Three Parallel Access Channels 3 pp
- Hospital pharmacy committee, private VHI, and NPHC exceptional access compared
- Approval timelines and price basis at each channel
-
3 · VHI Channel Economics — Bupa Arabia PA Criteria 3 pp
- The 2023 PA criteria and MGFA-TC composite-score threshold
- The 60-70% approval rate this criteria set produces
-
4 · Analogue Benchmarks — SC Versus IV Formulation Pricing 3 pp
- The subcutaneous formulation's roughly 80%-of-IV price differential
- What the analogue set supports for a new entrant's own formulation strategy
-
5 · NPHC Exceptional-Access Threshold & the 2025-2026 Catalyst 3 pp
- The SAR 180,000-250,000/yr exceptional-access threshold as the pre-formulary price anchor
- argenx's active NPHC engagement and the formulary-designation timeline
-
6 · GTN Waterfall & Channel-Mix Revenue Modelling 3 pp
- Revenue modelled across the three channels' differing volumes and prices
- The channel-mix shift expected once NPHC formulary coverage lands
-
7 · Launch Sequencing & Revenue Scenarios 4 pp
- Channel-prioritisation sequencing across KSA, UAE, Qatar, and the wider GCC
- Conservative, base, and aggressive revenue scenarios tied to the NPHC timeline
-
8 · Client Alignment Questions 2 pp
- The open pricing questions your team must close before the GCC channel strategy is locked
- Structured for an internal pricing committee session
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom model delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this model
AXLRx delivers myasthenia gravis pricing strategy models built for market access and pricing teams navigating GCC's three-channel access structure. Custom model in 72 hours.
- 1. Submit your requestSpecify your indication, target GCC market, and channel priority.
- 2. Scoping callAXLRx analyst confirms channel-pricing assumptions and NPHC-timeline scope before building.
- 3. DeliveryResearch-verified pricing model in 72 hours with optional analyst readout.
How AXLRx builds this model
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx pricing model is built from primary regulatory and payer sources, SFDA and NPHC programme documentation, and private-insurer PA policy, not secondary summaries. Findings are independently verified before inclusion.
GCC myasthenia gravis pricing sources: argenx GCC market access documentation, NPHC programme scope documentation, and Bupa Arabia's 2023 formulary and PA criteria.
- Efgartigimod per-cycle and annual pricing verified against argenx GCC pricing data
- Bupa Arabia PA criteria and approval rate verified against its 2023 formulary and PA policy documentation
- NPHC exceptional-access threshold and the 2025-2026 formulary timeline verified against NPHC programme scope documentation
Frequently asked questions
Deliverables What formats are included with every model?
Every commissioned Pricing Strategy Model includes an editable 8-sheet Excel model (Price Ladder, VHI Channel Economics, Analogue Benchmarks, NPHC Threshold Analysis, GTN Waterfall, Launch Sequencing, Revenue Scenarios, Sources) and a PDF methodology brief, no PowerPoint deck, since a pricing model is built to be worked in directly rather than presented from. An optional 45-minute analyst readout call is included.
Sources How is the pricing evidence verified?
AXLRx builds from primary sources only: SFDA and NPHC programme documentation, private-insurer PA policy, and argenx GCC market access data. No secondary summaries or market research reports.
Customisation Can I model a specific GCC country or payer channel?
Yes. The intake form captures your indication, target GCC market, and comparator channel. A scoping call confirms scope before research starts. Commission via the intake form to start.